Immuneering Comments on FDA Approval of Pancreatic Cancer Drug
The U.S. Food and Drug Administration approved daraxonrasib, marketed as Rasonque by Revolution Medicines, as a targeted therapy for adults with advanced pancreatic cancer whose previous…